Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Exactly it wont happen right
Will this. Merger be done this year
Dr fatso too greedy so he brought all us down with him
I think they have no intention of going thru with the merger
The people who invested in ANEW when it was private are the ones who are going to own the bulk of it. That's been very clear from the RM a couple years ago with the nearly immediate announcement of the 1-2500 RS and the change to the corporate charter to reflect it and the award of the preferred B shares to those investors in ANEW with a 100-1 conversion into commons. The RS reduced the O/S of about 1B shares down to 400,000 shares, and the conversion of the preferred B's would make 40M common shares, so the legacy shareholders of LEAS would get roughly 1% of the company. That makes perfect sense, since nobody holding LEAS shares has given ANEW a plug nickel, they hold and trade shares sold by the failed businesses that once occupied LEAS and for which the cash raised from the initial sale is long gone.
So, no, the LEAS holders are not entitled to a significant portion of the RWOD/WENA stock.
So all leas holders are pretty much fucked
Don't know. I'd bet they're getting the story straight for the exchange of stock. I've said all along the common shareholders of LEAS were going to be RS'd one way or another since the Dr. had been very public about what he was up to, but the naive who thought they'd found a "sure thing" on the OTC and didn't actually read through the financials for themselves are still going to whine about it.
On the other hand, you do know that virtually all the retail common stock of RWOD was redeemed for cash, right? That means that the Dr. is merging his company into a shell with no cash to do anything with now, and carries the burden of the founders share holdings, effectively giving a significant part of his company to them for nothing. Cash in the treasury is why some companies do these business combinations, without it, it may not be worth it. If they have to turn around and do a stock offering to raise money, it ain't gonna be at $10 per share.
Why would they keep extending this trader?
He must be referring to the outcome of a 1-2500 reverse split of the common stock followed by a 100-1 conversion of the preferred B shares described in every quarterly/annual report. That works out to 1-250000, of course, so if he only does 1-25000, it means that instead of the preferred B shareholders getting 99% of the WENA stock, they'd only get 90%....
But whats causing the god dam delay? Also what conversion do u see happening?
They don't have a choice
I see no filling at the Wyoming SOS that could allow them to further reverse split LEAS by 1:10 (The only way they can get to 1:25000 like Sinkule is circulating)
RWOD fillings are lacking a proper description of the Exchange Ratio, in my opinion. (At the very least they should tell the shareholders how the LEAS Preferred B will be "treated")
https://wyobiz.wyo.gov/Business/FilingDetails.aspx?eFNum=023134109014071170057137212225204229086026117085
but not having the merger he loses money doesn't he?
We on expert market
Do you think he did?
So we all wonder and ponder if the doc did or did not scam us. Classic delay / stalling tactic.
why do they want to to delay this?
VERY UNLIKELY to be this week
Like other mentioned, it can be extended until December 4th 2024 (Likely going to be extended, by an extra month, at first)
The announcement, a day before it happens, should appear there:
https://www.nasdaqtrader.com/Trader.aspx?id=archiveheadlines&cat_id=105
or there:
https://otce.finra.org/otce/dailyList
When will merger happen
That's definitely true, that's always how SPAC DEAL works
Have you watched other SPAC deal?
The combined entity starts trading (Pre-market) at the price the SPAC last closed at, the day before (Check AGBA on November 3-4 2022)
Usually, the Market Makers makes sure the price stays close to 10$, before the closing, but sometimes they don't...
U think? This may get delayed further or we not get anything
He who is patient get big WENA.
This is some bullshit just tell us no your not getting the wena or tell us its delayed
Almost certain LEAS shareholders get WENA shares at 10$, but WENA opens at the price of RWOD on the prior day close, or whatever price it is at during pre-market.
Dude wena will open at 10…:: not rwod
RWOD isn't trading well right now will see soon. hope your trading other tickers theirs money to be made good luck :o)
Ya 1:2500 i mean..: best case it goes 10 and goes way up
don't know what its goin to be just try to help out :o)
you said 1 for 2500 make up your mind
Ok thanks but is this 1/25000 for sure??
so when you get your shares on nasdac they can be 10.00 a share 2000.00 and if the doctor has good plan moving forward your money can multiply or sell at any time. hope this helps :o)
not saying its good " yet"
Yea its called 200 shares now !! Wow
so you have half million shares and you get 1 for every 2500 shares = you tell me :o)
How is a 1:2500 rs good
you have a lot to learn. dont know how to help you
Expected what??? The 1:2500 rs we lose
I expected it I have a nuff shares ,not worried :o)
Well why dont you look smartass
Anyone smart like me check the Wyoming sos website? It says 1:2500 rs processed… fuck
Well do you see any news??
+>>>LEAS- What an absolutely asinine fool you are. Bag holders belong at Walmart pal not on ihub speculating on the size of peoples positions.
LMFAO
Whatever the case children... i'll be waiting here till the 4th and we'll see what happens.
Chin up People Chin Up
CC
Extension past 6/4 looks inveitable
Medical product development and commercialization. The Company recently acquired five generic oncology drugs approved and manufactured in Germany and they plan to gain approval for these drugs in the US in 2023. The Company is preparing for a pivotal Phase 3 study of an anti-cancer antibody product that is highly similar to Genentech/Roche's brand name Avastin (bevacizumab), the Company has licensed a needle-free jet injector for drug delivery, and the Company is in the pre-clinical stages of development of a gene therapy product candidate based on the delivery of a human alpha-Klotho gene and protein to prevent and/or treat neurodegenerative diseases such as Alzheimer's and Lou Gehrig's disease (ALS). Other product candidates will stem from these platform technologies of pharmaceuticals, biologics, and gene therapy.
The Company's medical R&D facilities are in the U.S. (near the University of Nebraska Medical Center, Omaha, Nebraska) and in Barcelona, Spain (Autonomous Universitat de Barcelona). Each R&D facility is comprised of over 4,000 sq ft of R&D and office space, currently leased and equipped with research equipment, incubators, tissue culture facilities for production of plasmid DNA, HEPA-filtered hoods for aseptic handling, and testing equipment (PCR, spectrophotometers, microscopes, etc). The generic oncology drugs are manufactured in Germany. With future funding, the Company plans to acquire or build a GMP manufacturing facility to supply novel plasmid DNA ("transgenes") to be used in gene therapy programs, to provide contract manufacturing revenue, and for commercial product manufacturing.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |